Eli Lilly announced its financial results related to the acquisition of another company for a total of $2.8 billion for the third quarter. It is projected that the annual profit per share for Eli Lilly will range from $13.02 to $13.52, which is lower than the previous forecast of $16.10-16.60.
The company’s stock fell by 10% before the market opened, but then rebounded by 0.8%. Eli Lilly reported financial results that were below expectations for revenues and profits for the third quarter of 2024, influenced by a decline in sales of popular products for weight loss, "Zepbound" and diabetes medication "Mounjaro." Additionally, the company lowered its forecasts for the quarters for the financial year as a whole.
